FindTrial
Sign In

Aldoxorubicin HCl

DRUG7 trials

Sponsors

ImmunityBio, Inc.

Conditions

Metastatic Pancreatic CancerPancreatic CancerSquamous Cell CarcinomaTriple Negative Breast CancerTriple Negative Breast Cancer (TNBC)

Phase 1

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
TerminatedNCT03387098
ImmunityBio, Inc.Pancreatic Cancer
Start: 2017-12-28End: 2019-01-15Updated: 2024-05-22
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
TerminatedNCT03387085
ImmunityBio, Inc.Triple Negative Breast Cancer
Start: 2018-03-19End: 2024-01-16Updated: 2024-08-09
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
TerminatedNCT03387111
ImmunityBio, Inc.Squamous Cell Carcinoma
Start: 2018-01-09End: 2021-01-11Updated: 2024-08-05
QUILT-3.080: NANT Pancreatic Cancer Vaccine
TerminatedNCT03586869
ImmunityBio, Inc.Pancreatic Cancer
Start: 2018-07-17End: 2019-08-01Updated: 2024-08-27

Phase 2

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
WithdrawnNCT03554109
ImmunityBio, Inc.Triple Negative Breast Cancer (TNBC)
Start: 2018-09-30End: 2022-02-09Updated: 2025-02-21
QUILT-3.088: NANT Pancreatic Cancer Vaccine
WithdrawnNCT03563144
ImmunityBio, Inc.Metastatic Pancreatic Cancer
Start: 2018-08-31End: 2022-02-09Updated: 2025-02-21
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Active, not recruitingNCT04390399
ImmunityBio, Inc.Pancreatic Cancer
Start: 2020-07-21End: 2026-05-31Target: 328Updated: 2025-12-15

Related Papers

Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3 <sup>rd</sup> line or greater metastatic pancreatic cancer.
Journal of Clinical Oncology2025-05-28
Abstract 5255: Systemic immunosuppression in pancreatic cancer
Cancer Research2025-04-21
Overall survival in patients with metastatic or locally advanced pancreatic cancer following chemoradiation with novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.
Journal of Clinical Oncology2023-01-246 citations
Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.
Journal of Clinical Oncology2022-06-015 citations
Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemo-radiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.
Journal of Clinical Oncology2022-01-195 citations
Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.
Journal of Clinical Oncology2021-05-203 citations
Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T-cell therapy in patients with third line or greater TNBC.
Journal of Clinical Oncology2019-05-204 citations
Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer.
Journal of Clinical Oncology2019-05-202 citations
Correlation between circulating cell-free RNA biomarkers and response during combination immunotherapy in previously refractory metastatic TNBC patients.
Journal of Clinical Oncology2019-05-201 citations
NANT cancer vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer.
Journal of Clinical Oncology2019-01-298 citations